Patents Examined by Cheom-Gil Cheong
-
Patent number: 11976130Abstract: The invention relates to antibodies directed against an epitope located within the C-terminal portion of CLDN18.2 which are useful, for example, in diagnosing cancer and/or in determining whether cancer cells express CLDN18.2.Type: GrantFiled: July 17, 2018Date of Patent: May 7, 2024Assignees: Astellas Pharma Inc., TRON—Translationale Onkologie an der Universitätsmedizin der JohannesInventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Woll
-
Patent number: 11965033Abstract: The present invention relates to a monoclonal mouse antibody produced by the hybridoma cell deposited under ICLC accession number ICLC PD n° 16001. Furthermore, the invention relates to an antibody comprising a heavy chain variable region comprising complementarity determining regions CDRH1, CDRH2 and CDRH3, and a light chain variable region comprising complementarity determining regions CDRL1, CDRL2 and CDRL3, wherein CDRH1, CDRH2, CDRH3, CDRL1, CDRL2, and CDRL3 comprise the amino acid sequences GFTFSSFGMH (SEQ ID NO: 1), YISSGSGNFYYVDTVKG (SEQ ID NO: 43), STYYHGSRGAMDY (SEQ ID NO: 3), SASSSVSSMYWY (SEQ ID NO: 4), DTSKMAS (SEQ ID NO: 5), and QQWSSYPPIT (SEQ ID NO: 6), respectively. In addition, the invention relates to antibodies recognizing the same epitope.Type: GrantFiled: October 5, 2021Date of Patent: April 23, 2024Assignee: UNIVERSITÀ DEGLI STUDI MAGNA GRAECIA CATANZAROInventor: Pierfrancesco Tassone
-
Patent number: 11945863Abstract: The present invention relates to a nucleic acid molecule encoding a chain myeloid capable of specifically binding to CD33, CD16 and CD123, wherein said nucleic molecule comprises: (a) a nucleic add molecule encoding a protein represented by SEQ ID NO:1; (b) a nucleic acid molecule represented by SEQ ID NO:2; (c) the nucleic add molecule of (b), wherein each thymine is replaced by urea; (d) a nucleic acid molecule encoding a protein having at least 98% sequence identity to the protein of (a); or (e) a nucleic add molecule that is degenerate with respect to the nucleic acid molecule of (b) or (c). The present invention further relates to a vector comprising the nucleic acid molecule of the invention, a host cell transformed or transfected with the nucleic acid molecule or the vector of the invention, as well as to a method for the production of a single chain myeloid capable of specifically binding to CD33, CD16 and CD123.Type: GrantFiled: December 1, 2017Date of Patent: April 2, 2024Assignee: Friedrich-Alexander-Universität Erlangen-NürnbergInventors: Georg H. Fey, Todd Braciak, Claudia C. Roskopf, Ingo Schubert, Karl-Peter Hopfner, Nadja Fenn, Sarah Wildenhain, Uwe Jacob
-
Patent number: 11946933Abstract: Mycobacterial-specific biomarkers and methods of using such biomarkers for diagnosis of mycobacterial infection in a mammal are disclosed.Type: GrantFiled: February 8, 2021Date of Patent: April 2, 2024Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventor: Adel M. Talaat
-
Patent number: 11939379Abstract: Chemically induced dimerizers (AbCIDs) have emerged as one of the most powerful tools to artificially regulate signaling pathways in cells; however, no facile method to identify or design these systems currently exists. The present invention provides a methodology to rapidly generate antibody-based chemically induced dimerizers (AbCIDs) from known small-molecule-protein complexes by selecting for synthetic antibodies that recognize the chemical epitope created by the bound small molecule. Success of this strategy is demonstrated by generating ten chemically-inducible antibodies against the BCL-xL/ABT-737 complex. Three of the antibodies are highly selective for the BCL-xL/ABT-737 complex over BCL-xL alone. Two exemplary important cellular applications of AbCIDs are demonstrated by applying them intracellularly to induce CRISPRa-mediated gene expression and extracellularly to regulate CAR T-cell activation with the small molecule, ABT-737.Type: GrantFiled: May 21, 2018Date of Patent: March 26, 2024Assignee: The Regents of the University of CaliforniaInventors: James A Wells, Zachary B. Hill, Alexander J. Martinko
-
Patent number: 11939385Abstract: The present application provides activatable antibodies comprising an antibody comprising an antigen-binding domain (ABD), wherein the ABD comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the N-terminus of the VH is fused to a first polypeptide shield moiety (S1), and the N-terminus of the VL is fused to a second polypeptide shield moiety (S2), wherein S1 comprises a first disease-sensing releasable moiety (DS1) and/or S2 comprises a second disease-sensing releasable moiety (DS2), wherein association of S1 with S2 blocks binding of the ABD to its target, and wherein the ABD does not specifically bind to S1, S2, or association thereof. Composition, methods of treatment using the activatable antibodies, and methods of preparation thereof are further provided.Type: GrantFiled: May 15, 2018Date of Patent: March 26, 2024Assignee: ALX ONCOLOGY INC.Inventors: Marija Vrljic, Jaume Pons
-
Patent number: 11913958Abstract: The present invention relates to methods for the in vitro diagnosis of lung cancer in a subject, comprising the detection of progastrin using at least one progastrin-binding antibody. According to the method of the invention, the subject is diagnosed with a lung cancer when progastrin is detected in the sample.Type: GrantFiled: March 30, 2018Date of Patent: February 27, 2024Assignee: ECS-Progastrin SAInventor: Alexandre Prieur
-
Patent number: 11866498Abstract: The present invention provides bispecific antigen-binding molecules having a monovalent arm specific to a first target antigen (e.g., a T cell antigen, such as CD3) and a bivalent arm specific for a second target antigen (e.g., a tumor antigen, such as HER2). Bispecific antigen-binding molecules are useful in the treatment of disorders, such as cancer (e.g., HER2-positive cancer). The invention also features methods of producing bispecific antigen-binding molecules, methods of treating disorders using bispecific antigen-binding molecules, and compositions including bispecific antigen-binding molecules.Type: GrantFiled: February 8, 2019Date of Patent: January 9, 2024Assignee: Genentech, Inc.Inventors: Diego Ellerman, Teemu T. Junttila, Twyla Noelle Lombana, Dionysos Slaga, Christoph Spiess
-
Patent number: 11827713Abstract: Provided is a chimeric antibody immune cell engager comprising a target cell binding domain that specifically binds to an antigen on a target cell, and an immune effector cell binding domain comprising an antigen-binding fragment that specifically binds to an antigen on an immune effector cell. Also provided are pharmaceutical compositions, kits and methods of treatment.Type: GrantFiled: June 27, 2018Date of Patent: November 28, 2023Assignee: Nanjing Legend Biotech Co., Ltd.Inventors: Xiaohu Fan, Qiuchuan Zhuang, Lei Yang, Pingyan Wang, Qingyan Li
-
Patent number: 11801288Abstract: The invention provides a vaccine comprising a nucleic acid molecule that encodes a dog telomerase reverse transcriptase (dTERT) antigen, as well as methods of using the vaccine to induce an immune response against a TERT and to treat cancer in a mammal.Type: GrantFiled: April 9, 2021Date of Patent: October 31, 2023Assignee: Inovio Pharmaceuticals, Inc.Inventor: Jian Yan
-
Patent number: 11795224Abstract: The present disclosure provides an anti-T-cell nanobody that specifically binds to CD3 ?. The present disclosure also provides the nucleic acid sequence of the anti-T-cell nanobody, use of the anti-T-cell nanobody for treating cancer, immunoregulation and activating immune cells, and a method for detecting expression levels of CD3 ?.Type: GrantFiled: March 18, 2022Date of Patent: October 24, 2023Assignee: CHINA MEDICAL UNIVERSITY HOSPITALInventors: Der-Yang Cho, Shao-Chih Chiu, Shi-Wei Huang, Chih-Ming Pan, Mei-Chih Chen, Yu-Chuan Lin, Yeh Chen
-
Patent number: 11795235Abstract: Disclosed is a molecule comprising: (a) a first domain, which comprises a targeting moiety; (b) a second domain, which comprises an albumin binding domain (ABD), (c) a third domain, which comprises a furin cleavage sequence (“FCS”), which FCS is cleavable by furin; and (d) a fourth domain, which comprises an optionally substituted Domain III from Pseudomonas exotoxin A (“PE”). Related nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, methods of producing the molecule, methods of treating or preventing cancer in a mammal, and methods of inhibiting the growth of a target cell are also disclosed.Type: GrantFiled: September 18, 2018Date of Patent: October 24, 2023Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Ira H. Pastan, Junxia Wei, Masanori Onda, Tapan Bera, Mitchell Ho
-
Patent number: 11787848Abstract: Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from a CD33 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders such as acute myeloid leukemia (AML), and relapsed or refractory AML.Type: GrantFiled: June 7, 2017Date of Patent: October 17, 2023Assignee: PRECIGEN, INC.Inventors: Rutul Shah, Tim Chan, Peter Emtage, Ramya Yarlagadda
-
Patent number: 11787862Abstract: The present invention provides binding agents comprising at least three binding domains, wherein a first binding domain binds to a T cell-specific antigen and a second binding domain and a third binding domain bind to a claudin, and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.Type: GrantFiled: September 20, 2017Date of Patent: October 17, 2023Assignees: BioNTech SE, ASTELLAS PHARMA INC.Inventors: Ugur Sahin, Christiane Stadler, Leyla Fischer, Arne Jendretzki, Özlem Türeci, Fabrice Le Gall, Maria Kreuzberg
-
Patent number: 11773171Abstract: The present invention provides Wnt pathway agonists and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of diseases.Type: GrantFiled: December 19, 2018Date of Patent: October 3, 2023Assignee: Surrozen Operating, Inc.Inventors: Yang Li, Tom Zhiye Yuan, Aaron Ken Sato, Wen-Chen Yeh, Claudia Yvonne Janda, Tristan William Fowler, Helene Baribault, Kuo-Pao Lai, Liqin Xie, Randall J. Brezski, Chenggang Lu
-
Patent number: 11746157Abstract: The present invention relates to antibodies specifically binding PSMA or PSMA and CD3, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.Type: GrantFiled: May 21, 2019Date of Patent: September 5, 2023Assignee: JANSSEN BIOTECH, INC.Inventors: Glenn Mark Anderson, Tammy Bush, Rosa Maria Fernandes Cardoso, Ellen Chi, Judith Ann Connor, Thai Quang Dinh, Derrick Lemon Domingo, John Michael Jones, Colleen Kane, Bethany Kay Mattson, Theresa Marie McDevitt, Jill Marie Mooney, Richard Stephen Tawadros, Hong Mimi Zhou
-
Patent number: 11739163Abstract: The present invention provides constructs comprising a plurality of peptides capable of targeting at least two different extracellular tumor antigens and a toxin, optionally connected to an organic scaffold. Use of such constructs in treating cancer are provided as well. The invention also provides particular peptides binding certain extracellular tumor antigens as well as toxins having antitumor activity.Type: GrantFiled: September 27, 2017Date of Patent: August 29, 2023Assignee: AEBI LTD.Inventors: Ilan Morad, Hanan Itzhaki
-
Patent number: 11739159Abstract: The present invention relates to an anti-MUC1 antibody binding specifically to Mucin 1 (MUC1) or an antigen-binding fragment thereof, an antibody-drug conjugate or bispecific antibody comprising the antibody, a pharmaceutical composition for prevention or treatment of cancer, comprising the same antibody, conjugate or bispecific antibody, and a nucleic acid encoding the same antibody, a vector and a host cell, both carrying the same nucleic acid, and a method for preparing an anti-MUC1 antibody or an antigen-binding fragment thereof, using the same vector and host cell. According to the present invention, the antibody shows outstanding affinity and binding force to MUC1 and the antibody-drug conjugate can bind specifically to a MUC1-expressing cell to specifically or selectively transfer the drug with efficacy. Therefore, the anti-MUC1 antibody and the antibody-drug conjugate according to the present invention can be usefully applied to the treatment of a MUC1-related disease, for example, cancer.Type: GrantFiled: July 12, 2022Date of Patent: August 29, 2023Assignee: PEPTRON, INC.Inventors: Kyung Duk Moon, Ho Il Choi
-
Patent number: 11739158Abstract: The present invention relates to an anti-MUC1 antibody binding specifically to Mucin 1 (MUC1) or an antigen-binding fragment thereof, an antibody-drug conjugate or bispecific antibody comprising the antibody, a pharmaceutical composition for prevention or treatment of cancer, comprising the same antibody, conjugate or bispecific antibody, and a nucleic acid encoding the same antibody, a vector and a host cell, both carrying the same nucleic acid, and a method for preparing an anti-MUC1 antibody or an antigen-binding fragment thereof, using the same vector and host cell. According to the present invention, the antibody shows outstanding affinity and binding force to MUC1 and the antibody-drug conjugate can bind specifically to a MUC1-expressing cell to specifically or selectively transfer the drug with efficacy. Therefore, the anti-MUC1 antibody and the antibody-drug conjugate according to the present invention can be usefully applied to the treatment of a MUC1-related disease, for example, cancer.Type: GrantFiled: July 11, 2022Date of Patent: August 29, 2023Assignee: PEPTRON, INC.Inventors: Kyung Duk Moon, Ho Il Choi
-
Patent number: 11732022Abstract: Provided herein are immunomodulatory proteins comprising variant PD-L2 and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological and oncological conditions. Compositions and methods for making and using such proteins are provided.Type: GrantFiled: March 13, 2018Date of Patent: August 22, 2023Assignee: Alpine Immune Sciences, Inc.Inventors: Ryan Swanson, Michael Kornacker, Mark F. Maurer, Dan Ardourel, Daniel William Demonte, Joseph L. Kuijper